WEEKLY EPIDEMIOLOGY BULLETIN


NATIONAL SURVEILLANCE UNIT, MINISTRY OF HEALTH & WELLNESS, JAMAICA

Weekly Spotlight

Tuberculosis (Part 1)

Tuberculosis (TB) is an infectious disease caused by bacteria that most often affects the lungs. It spreads through the air when people with TB cough, sneeze or spit. Tuberculosis is preventable and curable. About a quarter of the global population is estimated to have been infected with TB bacteria. About 5-10% of people infected with TB will eventually get symptoms and develop TB disease.

Development of Tuberculosis (TB)



Those who are infected but free of disease cannot transmit it. TB disease is usually treated with antibiotics and can be fatal without treatment. In certain countries, the Bacille Calmette-Guérin (BCG) vaccine is given to babies or small children to prevent TB. The vaccine prevents deaths from TB and protects children from serious forms of TB. Certain conditions can increase a person's risk for TB disease:

- diabetes (high blood sugar)
- weakened immune system (for example, from HIV or AIDS)
- being malnourished
- tobacco use
- harmful use of alcohol.

Symptoms

People with TB infection don't feel sick and aren't contagious. Only a small proportion of people who get infected with TB will get TB disease and symptoms. Babies and children are at higher risk. TB disease occurs when bacteria multiply in the body and affect different organs. TB symptoms may be mild for many months, so it is easy to spread TB to others without knowing it. Some people with TB disease do not have any symptoms.

Common symptoms of TB are:

- prolonged cough (sometimes with blood)
- chest pain
- weakness
- fatigue
- · weight loss
- fever
- night sweats

The symptoms people get depend on which part of the body is affected by TB. While TB usually affects the lungs, it can also involve the kidneys, brain, spine and skin.

Taken from WHO website on 25/Jun/2025 https://www.who.int/news-room/fact-sheets/detail/tuberculosis picture from https://iplungclinic.com/condition/tuberculosis/

EPI WEEK 24



Syndromic Surveillance

Accidents


Violence

Pages 2-4



Class 1 Notifiable Events

Page 5



COVID-19

Page 6



Influenza

Page 7



Dengue Fever

Page 8



Research Paper

Page 9

SENTINEL SYNDROMIC SURVEILLANCE

Sentinel Surveillance in Jamaica

A syndromic surveillance system is good for early detection of and response to public health events.



Sentinel surveillance occurs when selected health facilities (sentinel sites) form a network that reports on certain health conditions on a regular basis, for example, weekly. Reporting is mandatory whether or not there are cases to report.

Jamaica's sentinel surveillance system concentrates on visits to sentinel sites for health events and syndromes of national importance which are reported weekly (see pages 2 -4). There are seventy-eight (78) reporting sentinel sites (hospitals and health centres) across Jamaica.

Table showcasing the Timeliness of Weekly Sentinel Surveillance Parish Reports for the Four Most Recent Epidemiological Weeks – 21 to 24 of 2025

Parish health departments submit reports weekly by 3 p.m. on Tuesdays. Reports submitted after 3 p.m. are considered late.

KEY:

Yellow- late submission on Tuesday

Red – late submission after Tuesday


Epi week	Kingston and Saint Andrew	Saint Thomas	Saint Catherine	Portland	Saint Mary	Saint Ann	Trelawny	Saint James	Hanover	Westmoreland	Saint Elizabeth	Manchester	Clarendon
2025													
	On	On	On	On	On	On	On	On	On	On	On	On	On
21	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
	On	On	On	On	On	On	On	On	On	On	On	On	On
22	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
	On	On	On	On	On	On	On	On	On	On	On	On	On
23	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time
	On	On	On	On	On	On	On	On	On	On	On	On	On
24	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time	Time


REPORTS FOR SYNDROMIC SURVEILLANCE

UNDIFFERENTIATED FEVER

Temperature of $>38^{\circ}C$ /100.4°F (or recent history of fever) with or without an obvious diagnosis or focus of infection.









INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued





FEVER AND NEUROLOGICAL

Temperature of >38°C /100.4°F (or recent history of fever) in a previously healthy person with or without headache and vomiting. The person must also have meningeal irritation, convulsions, altered consciousness, altered sensory manifestations or paralysis (except AFP).



FEVER AND HAEMORRHAGIC

Temperature of $>38^{\circ}C$ /100.40F (or recent history of fever) in a previously healthy person presenting with at least one haemorrhagic (bleeding) manifestation with or without jaundice.




FEVER AND JAUNDICE

Temperature of $>38^{\circ}C/100.4^{\circ}F$ (or recent history of fever) in a previously healthy person presenting with jaundice.


The epidemic threshold is used to confirm the emergence of an epidemic in order to implement control measures. It is calculated using the mean reported cases per week plus 2 standard deviations.




Weekly Visits to Sentinel Sites for Fever and Neurological Symptoms 2024 and 2025 vs. Weekly Threshold: Jamaica



Weekly visits to Sentinel Sites for Fever and Haemorrhagic symptoms 2024 and 2025 vs Weekly Threshold; Jamaica



Weekly visits for Fever and Jaundice symptoms: Jamaica, Weekly Threshold vs Cases 2024 and 2025









INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events




HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



ACCIDENTS

Any injury for which the cause is unintentional, e.g. motor vehicle, falls, burns, etc.





VIOLENCE

Any injury for which the cause is intentional, e.g. gunshot wounds, stab wounds, etc.




Weekly Visits to Sentinel Sites for Violence by Age Groups 2025 vs. Weekly **Threshold** 800 700 600 Number of Visits 500 400 300 200 100 Λ 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 Epidemiological Week ■<5 y.o ≥5 y.o •Epi Threshold <5 y/o - Epi Threshold ≥5y/o

GASTROENTERITIS

Inflammation of the stomach and intestines, typically resulting from bacterial toxins or viral infection and causing vomiting and diarrhoea.









INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



June 27, 2025 ISSN 0799-3927

CLASS ONE NOTIFIABLE EVENTS Comments Confirmed YTD^{α} AFP Field Guides from WHO indicate that for an **CURRENT PREVIOUS** CLASS 1 EVENTS effective surveillance YEAR 2025 **YEAR 2024** system, detection rates for **Accidental Poisoning** 39^β 198^{β} AFP should be 1/100,000 population under 15 years Cholera 0 0 NATIONAL /INTERNATIONAL old (6 to 7) cases annually. Severe Dengue^y See Dengue page below See Dengue page below COVID-19 (SARS-CoV-2) 190 273 Pertussis-like syndrome and INTEREST Tetanus are clinically 0 0 Hansen's Disease (Leprosy) confirmed classifications. 2 21 Hepatitis B 7 ∨ Dengue Hemorrhagic Hepatitis C 1 Fever data include Dengue HIV/AIDS NA NA related deaths: 0 0 Malaria (Imported) δ Figures include all deaths 6 11 Meningitis associated with pregnancy 1 0 Monkeypox reported for the period. EXOTIC/ 0 0 Plague UNUSUAL ^ε CHIKV IgM positive 0 0 Meningococcal Meningitis MORBIDITY cases **Neonatal Tetanus** 0 0 ^θ Zika PCR positive cases Typhoid Fever 0 0 ^β Updates made to prior Meningitis H/Flu 0 0 ^α Figures are cumulative AFP/Polio totals for all epidemiological Congenital Rubella Syndrome weeks year to date. Congenital Syphilis SPECIAL PROGRAMMES Fever and Measles Rash Rubella Maternal Deaths^δ 27 31 Ophthalmia Neonatorum 91 Pertussis-like syndrome Rheumatic Fever Tetanus 27 Tuberculosis Yellow Fever Chikungunya^e 0 Zika Virus^θ







INVESTIGATION **REPORTS-** Detailed Follow up for all Class One Events



HOSPITAL ACTIVE 30 sites. Actively pursued



SENTINEL REPORT- 78 sites. Automatic reporting


NA- Not Available

June 27, 2025 ISSN 0799-3927

COVID-19 Surveillance Update

		COVID		
CASES	EW 24	Total		
Confirmed	11	157627		
Females	6	90821		
Males	5	66803		
Age Range	5 to 98 years	1 day to 108 years		
* 2 positive sesse had no conder enecification				

- * 3 positive cases had no gender specification
- * PCR or Antigen tests are used to confirm cases
- * Total represents all cases confirmed from 10 Mar 2020 to the current Epi-Week.




COVID-19 Outcomes

Outcomes	EW 24	Total		
ACTIVE *2 weeks*		28		
DIED – COVID Related	0	3879		
Died - NON COVID	0	396		
Died - Under Investigation	0	142		
Recovered and discharged	0	103226		
Repatriated	0	93		
Total		157627		

*Vaccination programme March 2021 - YTD

* Total as at current Epi week


3315 COVID-19 Related Deaths since March 1, 2021 – YTD Vaccination Status among COVID-19 Deaths



COVID-19 Parish Distribution and Global Statistics

SARS-CoV-2 Spike (S) Nucleocapsid (N) Membrane (M) Envelope (E) RNA viral genome

COVID-19 WHO Global Statistics EW 21 -24, 2025					
Epi Week	Confirmed Cases	Deaths			
21	64200	247			
22	60600	207			
23	97500	216			
24	136000	228			
Total (4weeks)	358300	898			



NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued




NATIONAL SURVEILLANCE UNIT INFLUENZA REPORT

EW 24


June 8, 2025 – June 14, 2025 Epidemiological Week 24

	EW 24	YTD
SARI cases	7	223
Total Influenza positive Samples	2	164
Influenza A	1	140
H1N1pdm09	0	76
H3N2	1	64
Not subtyped	0	0
Influenza B	1	24
B lineage not determined	0	0
B Victoria	1	24
Parainfluenza	0	0
Adenovirus	0	0
RSV	0	30



Epi Week Summary


During EW 24, seven (7) SARI admissions were reported.



Caribbean Update EW 24

Caribbean: Influenza activity, primarily driven by A(H1N1)pdm09, has increased over the past two weeks, with a positivity rate of 11.7%, along with rising numbers of ILI and SARI cases associated with influenza across the subregion. In Haiti, influenza activity continued its upward trend, reaching a positivity rate of 28.3%, while remaining at interseasonal levels in Belize and the Dominican Republic. RSV positivity remains low throughout the subregion. SARS-CoV-2 activity remains elevated but stable overall, with positivity rates of 23. 2% and 25% respectively, and remains elevated in the Dominican Republic, Jamaica, Saint Lucia and Barbados. In Guyana, SARS-CoV-2 activity also continued to rise with a positivity rate of 13.3% along with an increased proportion of ILI and SARI cases associated with SARS-CoV-2.

(taken from PAHO Respiratory viruses weekly report) https://www.paho.org/en/influenza-situation-report



7 NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued




Dengue Bulletin

June 8, 2025 – June 14, 2025 Epidemiological Week 24

Epidemiological Week 24





Reported suspected, probable and confirmed dengue with symptom onset in week 24 of 2025


	2025*			
	EW 24	YTD		
Total Suspected, Probable & Confirmed Dengue Cases	1	218		
Lab Confirmed Dengue cases	0	0		
CONFIRMED Dengue Related Deaths	0	0		

Symptoms of Dengue fever Febrile phase Critical phase sudden-onset fever hypotension headache pleural effusion ascites mouth and nose bleeding gastrointestinal bleeding muscle and joint pains Recovery phase altered level of vomiting consciousness seizures rash itching diarrhea slow heart rate

Points to note:

- Dengue deaths are reported based on date of death.
- *Figure as at June 27, 2025
- Only PCR positive dengue cases are reported as confirmed.
- IgM positive cases are classified as presumed dengue.

Suspected, probable and confirmed dengue cases for 2023-2025 versus monthly mean, alert and epidemic threshold (2007-2022)







INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



June 27, 2025 ISSN 0799-3927

RESEARCH PAPER

Abstract

NHRC-23-O21

Patient satisfaction and factors influencing satisfaction in accident and emergency departments of type A hospitals in Jamaica.

Linton S¹, Burke-Grant T¹, Wright S¹, Lynch L¹, Holder C¹, Thompson C¹

Objective: To determine the level of patient satisfaction, and factors influencing satisfaction in Accident and Emergency Departments of Type A hospitals in Jamaica.

Methods: a cross-sectional was done from May to July 2023. Two hundred and sixty-seven patients were selected randomly from accident and emergency departments of the three type A hospitals in Jamaica. A modified emergency department consumer assessment of healthcare providers and systems (Ed CAHPS) tool was used to collect data on sociodemographic characteristics, wait times, and perceptions on getting timely care, how well doctors and nurses communicated and communication about medications and follow-up. An overall satisfaction rating was provided. Patient satisfaction composite scores were computed, and chi square test and t-test were used to determine associations with sociodemographic characteristics. A p-value of ≤ 0.05 was deemed statistically significant. All patients provided informed consent and ethical approval was received for the study.

Results: The mean composite score for 'getting timely care' was 66.3/100; 'how well doctors and nurses communicate -76.0/100; communication about medication -66.3/100 and communication about follow-up -63.3/100. 52.1% of patients estimated wait time from registration to completion of care of > 6 hours, and 54.7% reported not receiving medical within 30 minutes of their visit. The average satisfaction score at 78%. There was no association between patient satisfaction and sociodemographic characteristics of patients.

Conclusion: Patients were generally satisfied with communication from doctors and nurses. Human resource quantity, training and process flow should be considered in improving timeliness of care and communication about medication and follow-up.



The Ministry of Health and Wellness *15 Knutsford Boulevard*, Kingston 5, Jamaica Tele: (876) 633-7924

Email: surveillance@moh.gov.jm



NOTIFICATIONS-All clinical sites



INVESTIGATION REPORTS- Detailed Follow up for all Class One Events



HOSPITAL ACTIVE SURVEILLANCE-30 sites. Actively pursued



¹ University of the West Indies, Mona, Jamaica